Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca2+ regulation

Heart Rhythm

Volumn 6, Issue 11, 2009, Pages 1652-1659

  Cerrone, Marina ^a   Napolitano, Carlo ^a,b   Priori, Silvia G ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b IRCCS   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CALCIUM CHANNEL; CATECHOLAMINE;

ARRHYTHMOGENESIS; ARTICLE; CARDIAC PATIENT; CATECHOLAMINE SYNTHESIS; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CLINICAL FEATURE; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG TARGETING; ENZYME REGULATION; EXERCISE TEST; GENE CONTROL; GENE MUTATION; HEART ARRHYTHMIA; HEART FAILURE; HOMEOSTASIS; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN TARGETING;

ANIMALS; CALCIUM; CATECHOLAMINES; HUMANS; MICE; PEDIGREE; POLYMORPHISM, GENETIC; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; TACHYCARDIA, VENTRICULAR;

EID: 70350505897     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.06.033     Document Type: Article

References (41)

1. Leenhardt A., Lucet V., Denjoy I., Grau F., Ngoc D.D., and Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 91 (1995) 1512-1519
2. Coumel P., Fidelle J., Lucet V., Attuel P., and Bouvrain Y. Catecholamine-induced severe ventricular arrhythmias with Adam-Stokes in children: report of four cases. Br Heart J 40 Suppl (1978) 28-37
3. Priori S.G., Napolitano C., Tiso N., et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103 (2001) 196-200
4. Lahat H., Pras E., Olender T., et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69 (2001) 1378-1384
5. Priori S.G., Napolitano C., Memmi M., et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106 (2002) 69-74
6. Cerrone M., Colombi B., Bloise R., et al. Clinical and molecular characterization of a large cohort of patients affected with catecholaminergic polymorphic ventricular tachycardia. Circulation 110 Suppl (2004) 552
7. Monteforte N., Raytcheva-Buono E., Bloise R., et al. Electrocardiographic analysis of arrhythmias developing during exercise in patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 116 (2007) 492
8. Sumitomo N., Sakurada H., Taniguchi K., et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 71 (2007) 1606-1609
9. Swan H., Piippo K., Viitasalo M., et al. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 34 (1999) 2035-2042
10. Tester D.J., Arya P., Will M., et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 3 (2006) 800-805
11. di Barletta M.R., Viatchenko-Karpinski S., Nori A., et al. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 114 (2006) 1012-1019
12. Bhuiyan Z.A., Hamdan M.A., Shamsi E.T., et al. A novel early onset lethal form of catecholaminergic polymorphic ventricular tachycardia maps to chromosome 7p14-p22. J Cardiovasc Electrophysiol 18 (2007) 1060-1066
13. Cerrone M., Colombi B., Santoro M., et al. Bidirectional ventricular tachycardia and fibrillation elicited in a knock-in mouse model carrier of a mutation in the cardiac ryanodine receptor. Circ Res 96 (2005) e77-e82
14. Kannankeril P.J., Mitchell B.M., Goonasekera S.A., et al. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci U S A 103 (2006) 12179-12184
15. Lehnart S.E., Mongillo M., Bellinger A., et al. Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118 (2008) 2230-2245
16. Knollmann B.C., Chopra N., Hlaing T., et al. Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 116 (2006) 2510-2520
17. Song L., Alcalai R., Arad M., et al. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 117 (2007) 1814-1823
18. Liu N., Colombi B., Memmi M., et al. Arrhythmogenesis in catecholaminergic polymorphic ventricular tachycardia: insights from a RyR2 R4496C knock-in mouse model. Circ Res 99 (2006) 292-298
19. Cerrone M., Noujaim S.F., Tolkacheva E.G., et al. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 101 (2007) 1039-1048
20. Paavola J., Viitasalo M., Laitinen-Forsblom P.J., et al. Mutant ryanodine receptors in catecholaminergic polymorphic ventricular tachycardia generate delayed afterdepolarizations due to increased propensity to Ca2+ waves. Eur Heart J 28 (2007) 1135-1142
21. Jiang D., Xiao B., Zhang L., and Chen S.R. Enhanced basal activity of a cardiac Ca2+ release channel (ryanodine receptor) mutant associated with ventricular tachycardia and sudden death. Circ Res 91 (2002) 218-225
22. Jiang D., Xiao B., Yang D., et al. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). Proc Natl Acad Sci U S A 101 (2004) 13062-13067
23. Jiang D., Wang R., Xiao B., et al. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death. Circ Res 97 (2005) 1173-1181
24. Fernandez-Velasco M., Rueda A., Rizzi N., et al. Increased Ca2+ sensitivity of the ryanodine receptor mutant RyR2R4496C underlies catecholaminergic polymorphic ventricular tachycardia. Circ Res 104 (2009) 201-209
25. Ikemoto N., and Yamamoto T. Regulation of calcium release by interdomain interaction within ryanodine receptors. Front Biosci 7 (2002) d671-d683
26. Oda T., Yano M., Yamamoto T., et al. Defective regulation of interdomain interactions within the ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 111 (2005) 3400-3410
27. George C.H., Jundi H., Walters N., Thomas N.L., West R.R., and Lai F.A. Arrhythmogenic mutation-linked defects in ryanodine receptor autoregulation reveal a novel mechanism of Ca2+ release channel dysfunction. Circ Res 98 (2006) 88-97
28. Marx S.O., Reiken S., Hisamatsu Y., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 (2000) 365-376
29. Wehrens X.H., Lehnart S.E., Reiken S.R., et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2. Science 304 (2004) 292-296
30. George C.H., Higgs G.V., and Lai F.A. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes. Circ Res 93 (2003) 531-540
31. Hunt D.J., Jones P.P., Wang R., et al. K201 (JTV519) suppresses spontaneous Ca2+ release and [3H]ryanodine binding to RyR2 irrespective of FKBP12.6 association. Biochem J 404 (2007) 431-438
32. Kim E., Youn B., Kemper L., et al. Characterization of human cardiac calsequestrin and its deleterious mutants. J Mol Biol 373 (2007) 1047-1057
33. Terentyev D., Nori A., Santoro M., et al. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res 98 (2006) 1151-1158
34. Rizzi N., Liu N., Napolitano C., et al. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res 103 (2008) 298-306
35. Hayashi M., Denjoy I., Extramiana F., et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119 (2009) 2426-2434
36. Swan H., Laitinen P., Kontula K., and Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 16 (2005) 162-166
37. Sumitomo N., Harada K., Nagashima M., et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 89 (2003) 66-70
38. Rosso R., Kalman J.M., Rogowski O., et al. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4 (2007) 1149-1154
39. Watanabe H., Chopra N., Laver D., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15 (2009) 380-383
40. Wilde A.A., Bhuiyan Z.A., Crotti L., et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med 358 (2008) 2024-2029
41. R4496C+/- knock-in mice. Heart Rhythm 4 Suppl (2007) S107-S108